Peer-influenced content. Sources you trust. No registration required. This is HCN.

Trending Topics:
DIET & NUTRITION PATIENT EDUCATION OBESITY/WEIGHT MANAGEMENT EXERCISE/TRAINING LEGAL MATTERS GUIDELINES/RECOMMENDATIONS

MDLinxALZ-801 Trial Results Announced: A Breakthrough in Alzheimer’s Treatment?

On September 20, 2022, Alzheon Inc. announced promising results from its phase 2 trial of oral ALZ-801 (valiltramiprosate) in patients with early AD. The drug decreased p-tau181 levels, reduced brain atrophy, and improved cognitive skills in the trial.

Was this Essential useful?

More Essentials From

Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine (CCJM)
Clinical Advisor
Consultant360
Epoch Health
GoodRx for Healthcare Professionals
Healthgrades for Professionals
Healthline
Journal of the American College of Cardiology (JACC)
MDLinx
Mayo Clinic
MedCentral
Medical News Today (MNT)
Medical Professionals Reference (MPR)
Neurology Advisor
Northwestern Medicine
Oncology Learning Network
Oncology News Central (ONC)
Practical Neurology
Psych Congress Network
Psychiatrist.com
ReachMD
Verywell Health
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form